Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Loss Per Share of Common Stock

Loss Per Share of Common Stock

6 Months Ended

Jun. 30, 2023

The following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net loss per share computations:


	Six Months Ended June 30, (Unaudited)
		2023		2022
Basic EPS and diluted EPS:

Loss (Numerator)
Net loss		$	(8,279,020)	$	(6,462,677)

Shares (Denominator)
Weighted average common shares outstanding		956,804,028		495,874,560
Per-Share Amount		$	(0.01)	$	(0.01)

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:


	Three Months Ended June 30, (Unaudited)		Six Months Ended June 30, (Unaudited)
	2023	2022	2023	2022
Stock options	37,975,750	37,755,000	37,975,750	37,755,000
Common shares underlying convertible debt	—	5,570,932	—	5,570,932
Warrants	153,848,014	136,187,225	153,848,014	136,187,225
Unvested restricted stock units	2,666,668	4,000,000	2,666,668	4,000,000